CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $46.16M, above the global median of $16.24M
- FinancialsAltman Z-Score 2.2: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.07BCNY456.94M · vs all stocks (USD)
Revenue (TTM)
1.72BCNY255.82M · vs all stocks (USD)
Profit Margin
-20.33%Beta
0.1390xvs all stocks
52-Week Change
-13.20%vs all stocks
Market Capitalization
3.07BCNY456.94M · vs all stocks (USD)
Enterprise Value
3.31BCNY492.65M · vs all stocks (USD)
Forward P/E
10.15xPrice to Sales (TTM)
1.82xPrice to Book (MRQ)
1.44xEnterprise to Revenue
1.93xGross Margin
57.92%Profit Margin
-20.33%Operating Margin
-1.70%Return on Assets (TTM)
-2.68%Return on Equity (TTM)
-14.59%Revenue (TTM)
1.72BCNY255.82M · vs all stocks (USD)
Revenue per Share (TTM)
2.20CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-28.40%Gross Profit (TTM)
989.42MCNY147.14M · vs all stocks (USD)
EBITDA (TTM)
72.42MCNY10.77M · vs all stocks (USD)
Net Income (TTM)
-349.70MCNY-52.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-22.02%Operating Cash Flow (TTM)
294.36MCNY43.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
310.39MCNY46.16M · vs all stocks (USD)
5-Year Average Dividend Yield
0.44%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
82.82MCNYFY2025 · Dec 31, 2025Revenue
1.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
751.46MCNYFY2025 · Dec 31, 2025Gross Profit
1.11BCNYFY2025 · Dec 31, 2025Operating Income
-93.56MCNY-13.91M · vs all stocks (USD)
Pre-tax Income
-311.75MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.59MCNYFY2025 · Dec 31, 2025Net Income
-335.34MCNYFY2025 · Dec 31, 2025EBIT
-288.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.42MCNYFY2025 · Dec 31, 2025Research & Development
84.27MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
778.69MCNYFY2025 · Dec 31, 2025Other Operating Expenses
31.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
23.37MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
784.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
784.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-335.34MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-47.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
-75.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
445.13MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-335.34MCNYFY2025 · Dec 31, 2025Other Non-cash Items
55.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
145.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
86.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-28.09MCNYFY2025 · Dec 31, 2025Sale of Investments
84.69KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.00MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
516.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-754.80MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.69MCNYFY2025 · Dec 31, 2025Other Financing Charges
-35.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-302.57MCNYFY2025 · Dec 31, 2025Shares Outstanding
791.93MSharesUpdated Aug 20, 2026Float Shares
580.25MSharesUpdated Aug 20, 2026% Held by Insiders
31.44%vs all stocks
% Held by Institutions
0.94%vs all stocks
Total Cash (MRQ)
489.90MCNY72.85M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6250CNYUpdated Aug 20, 2026Total Debt (MRQ)
715.15MCNY106.35M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3190xCurrent Ratio (MRQ)
1.70xBook Value per Share (MRQ)
2.75CNYUpdated Aug 20, 2026Total Assets
3.44BCNY511.84M · vs all stocks (USD)
Total Current Assets
1.45BCNYFY2025 · Dec 31, 2025Total Liabilities
1.17BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.99BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
262.36MCNYFY2025 · Dec 31, 2025Total Current Liabilities
908.88MCNYFY2025 · Dec 31, 2025Cash
435.79MCNYFY2025 · Dec 31, 2025Cash Equivalents
11.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
447.13MCNYFY2025 · Dec 31, 2025Accounts Receivable
167.34MCNYFY2025 · Dec 31, 2025Inventory
546.90MCNYFY2025 · Dec 31, 2025Accounts Payable
102.99MCNYFY2025 · Dec 31, 2025Short-term Debt
602.10MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.53MCNYFY2025 · Dec 31, 2025Long-term Debt
102.50MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
791.93MCNYFY2025 · Dec 31, 2025Retained Earnings
424.42MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.27BCNY337.66M · vs all stocks (USD)
Treasury Stock
25.00MCNYFY2025 · Dec 31, 202552-Week Low
2.85CNYUpdated Aug 20, 202652-Week High
5.27CNYUpdated Aug 20, 202652-Week Change
-13.20%vs all stocks
Beta
0.1390xvs all stocks
50-Day MA
3.42CNYUpdated Aug 20, 2026200-Day MA
3.93CNYUpdated Aug 20, 2026Avg 10-Day Volume
42.44MSharesUpdated Aug 20, 2026Avg 30-Day Volume
38.85MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.4500CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.58Profit Margin: -0.20
Financial Health
Altman Z-Score 2.2: grey zoneSignificant
Altman Z-Score: 2.20
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $46.16M, above the global median of $16.24MNotable
Levered free cash flow (USD): 46,158,755.983Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk